View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 14, 2021updated 12 Jul 2022 11:05am

AVM gets FDA approval to modify non-Hodgkin’s lymphoma/leukaemia trial

According to the trial modification, intermediate dose levels will be removed to conclude the dose-escalation part sooner.

The US Food and Drug Administration (FDA) has granted its approval to amend the protocol of AVM Biotechnology’s ongoing AVM0703-001 clinical trial of its drug, AVM0703, in non-Hodgkin’s lymphoma/leukaemia patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The initial protocol with a 3 x 3 design involved dose escalation of 3mg/kg for all the six cohorts, which varied from 6mg/kg to 21mg/kg.

Nearly three subjects were to be enrolled in each arm under an adaptive-design/expansion cohort trial.

The modified protocol removes three cohorts and reduces the interval between cohorts.

Removing the 9mg/kg, 12mg/kg and 15mg/kg dose cohorts and proceeding with the potentially efficient dose of 18mg/kg is vital for the trial, AVM noted.

According to the data from preclinical research and compassionate use, 18 to 21mg/kg dose of the drug could be effective for the expansion phase of the trial.

Eliminating intermediate dose levels is expected to expedite the completion of the dose-escalation part and facilitate the commencement of the efficacy part sooner than anticipated.

AVM Biotechnology chief regulatory officer Janet Rea said: “We are pleased that the FDA agreed with our proposal, which leveraged the safety data amassed from the ongoing study and expanded access (compassionate use) patient data obtained to date.

“This accelerates our clinical development programme and propels it toward an earlier NDA submission.”

The drug was well-tolerated clinically with mild and self-limiting side effects.

AVM noted that a single dose of AVM0703 induces the quick activation and mobilisation of novel gamma delta positive Natural Killer T (NKT) cells.

NKT cells show properties of innate and adaptive immunity. AVM-NKT cells could be utilised to address multiple serious conditions, including different cancers and autoimmune conditions such as type 1 diabetes.

In preclinical studies, AVM0703 showed a potential for synergistic activity with chemotherapy, facilitating a decrease in total chemotherapy cycles without compromising patient response.

Furthermore, AVM is developing AVM-NKT as an off-the-shelf cell therapy with extensive applications.

The company is also analysing AVM0703 for autoimmune diseases and various other indications. The plan is to directly launch the product in the market.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena